DLL3 and melanoma: DLL3 was found highly expressed in melanoma compared with normal skin (Chen and Yan, 2022), and using Rovalpituzumab tesirine, a DLL3-targeting antibody-drug conjugate, can have antitumor activity in melanoma patients (Mansfield et al., 2021).